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Abstract: Statins are a cornerstone in the pharmacological prevention of cardiovascular disease.
Although generally well tolerated, a small subset of patients experience statin-related myotoxicity
(SRM). SRM is heterogeneous in presentation; phenotypes include the relatively more common myalgias,
infrequent myopathies, and rare rhabdomyolysis. Very rarely, statins induce an anti-HMGCR positive
immune-mediated necrotizing myopathy. Diagnosing SRM in clinical practice can be challenging,
particularly for mild SRM that is frequently due to alternative aetiologies and the nocebo effect.
Nevertheless, SRM can directly harm patients and lead to statin discontinuation/non-adherence, which
increases the risk of cardiovascular events. Several factors increase systemic statin exposure and
predispose to SRM, including advanced age, concomitant medications, and the nonsynonymous
variant, rs4149056, in SLCO1B1, which encodes the hepatic sinusoidal transporter, OATP1B1. Increased
exposure of skeletal muscle to statins increases the risk of mitochondrial dysfunction, calcium signalling
disruption, reduced prenylation, atrogin-1 mediated atrophy and pro-apoptotic signalling. Rare variants
in several metabolic myopathy genes including CACNA1S, CPT2, LPIN1, PYGM and RYR1 increase
myopathy/rhabdomyolysis risk following statin exposure. The immune system is implicated in both
conventional statin intolerance/myotoxicity via LILRB5 rs12975366, and a strong association exists
between HLA-DRB1*11:01 and anti-HMGCR positive myopathy. Epigenetic factors (miR-499-5p,
miR-145) have also been implicated in statin myotoxicity. SRM remains a challenge to the safe and
effective use of statins, although consensus strategies to manage SRM have been proposed. Further
research is required, including stringent phenotyping of mild SRM through N-of-1 trials coupled to
systems pharmacology omics- approaches to identify novel risk factors and provide mechanistic insight.
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1. Introduction
Statins are oral hypolipidaemic drugs and amongst the most widely prescribed medications
worldwide [1]; in the United Kingdom (UK) alone, ~7 million patients take a statin [2]. The first agent,
mevastatin (ML-236B), was identified from Penicillium citrinum [3], but was never marketed due to
adverse effects. Lovastatin (LVT), isolated from Aspergillus terreus, received its marketing authorisation
in 1987 and was the first statin approved [4]. LVT also naturally occurs in certain foodstuffs including
red yeast rice [5] and oyster mushrooms [6].
Statins are the first line hypolipidaemic drug class for managing cardiovascular (CV) disease
(CVD), although ezetimibe, fibrates, bile acid sequestrants, and parenteral proprotein convertase
subtilisin/kexin type 9 (PSCK9) inhibitors are also used in specific situations. In the UK, atorvastatin
(ATV) 20 mg and 80 mg daily are the current first line guideline-recommended statins for primary and
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secondary CVD prevention, respectively [7]. However, due to historic prescribing, simvastatin (SVT)
remains the most commonly prescribed statin in the UK, followed by ATV [8].
Statins competitively inhibit 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR),
the rate limiting enzyme for de novo cholesterol synthesis in the mevalonate pathway (Figure 1).
In response, a compensatory upregulation in hepatic low-density lipoprotein (LDL) receptor cell
surface expression occurs [9], leading to a reduction in circulating LDL cholesterol (LDL-C) by
~30–63%, depending on statin and dose. Statins also reduce triglycerides (~20–40%) and raise
high-density lipoprotein-cholesterol (HDL-C) (~5%) to a modest extent [10]. Large meta-analyses of
statin randomized controlled trials (RCTs) have concluded that each 1 mmol/L reduction in LDL-C
with statin therapy is associated with a 22% reduction in the rate of major CV events (coronary deaths,
myocardial infarctions, strokes and coronary revascularisations) [11].
Beyond lowering cholesterol, statins have been associated with a range of beneficial pleiotropic
effects including anti-inflammatory, antioxidant and immunomodulatory effects, inhibition of platelet
activation, regulation of pyroptosis, and increased plaque stability [12–14]. For example, statins mediate
a dose-dependent decrease in C-reactive protein [15], may impact renal function [16,17], and attenuate
postpartum cardiovascular dysfunction in a rat preeclampsia model [18]. The mechanisms underlying
these effects are incompletely understood. However, decreases in other products of the mevalonate
pathway following statin-mediated HMGCR inhibition, including isoprenoid intermediates, dolichols,
heme A and coenzyme Q10 (CoQ10,) (Figure 1), are thought to play a role [12].
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(PVT), rosuvastatin (RVT), and SVT. Statins can be sub-divided into: (i) those administered as the 
therapeutically inactive lactone (LVT, SVT) versus those administered as active acid statin (ATV, 
FVT, PVT, PIT, RVT); (ii) those that undergo extensive metabolism by the phase I cytochrome P450 
(CYP) system (ATV, FVT, LVT, SVT) versus those excreted predominantly unchanged (PIT, PVT, 
RVT), and (iii) of the extensively metabolised statins, those primarily biotransformed by CYP3A4/5 
(ATV, LVT, SVT) or CYP2C9 (FVT). Table 1 provides an overview of the different statins.
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Seven statins are currently licensed: ATV, fluvastatin (FVT), LVT, pitavastatin (PIT), pravastatin
(PVT), rosuvastatin (RVT), a d SVT. Statins can be sub-divided into: (i) those administered as the
therapeutically inactive lactone (LVT, SVT) versus those a ministered as active acid statin (ATV, FVT,
PVT, PIT, RVT); (ii) those that undergo extensive metabolism by the phase I cytochrome P450 (CYP)
system (AT , FVT, LVT, SVT) versus those excreted predominantly unchanged (PIT, PVT, RVT), and
(iii) of the extensively metabolised statins, those primarily biotransformed by CYP3A4/5 (A V, LVT,
SVT) or CYP2C9 (FVT). Table 1 provides an overview of the different statins.
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Table 1. Pharmacokinetic properties of the different statins.
Drug Property Atorvastatin Cerivastatin Fluvastatin Lovastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin
Year approved 1996 1997 to 2001 1993 1987 2009 1991 2003 1991
Generic available Yes No Yes Yes No Yes No Yes
Daily dose (mg) 10–80 0.2–0.3 20–80 10–80 1–4 10–80 5–40 10–40
Equipotent dose (mg) 20 - >80 80 4 80 5 40
Marketed drug form Acid Acid Acid Lactone Acid Acid Acid Lactone
log P (N-octanol/H2O partition
coefficient) 1.11 (lipophilic) 1.70 (lipophilic) 1.27 (lipophilic) 1.70 (lipophilic) 1.49 (lipophilic) −0.84 (hydrophilic) −0.33 (hydrophilic) 1.60 (lipophilic)
Oral absorption (%) 30 >98 98 31 80 37 50 65–85
Bioavailability (%) 14 60 29 <5 51 17 20 5
Effect of food on bioavailability Decrease No effect Decrease Increase No effect Decrease No effect No effect
Time to Cmax (hours) 1–2 2–3 2.5–3 2 1 1–1.5 3–5 1–4
Protein binding (%) ≥98 >99 98 >95 >99 ~50 88 95
Volume of distribution 381 L 0.3 L/Kg 25 - 148 L 0.5 L/Kg 134 L 233 L
Extent of metabolism High High High High Low Low Low High
CYPs that metabolise statin acid form CYP3ACYP2C8 † CYP2C8 CYP3A
CYP2C9
CYP2C8 †
CYP3A †
CYP3A CYP2C9CYP2C8 †
CYP2C9
CYP3A †
CYP2C9
CYP2C19 †
CYP3A †
CYP3A
CYP2C8 †
CYPs that metabolise statin lactone form CYP3A CYP3A CYP3A CYP3A CYP3ACYP2D6 † Not known
CYP3A
CYP2C9 †
CYP2D6 †
CYP3A
UGTs involved in lactonization of statin
acid form
UGT1A1
UGT1A3
UGT2B7
UGT1A3 Not known UGT1A1UGT1A3
UGT1A3
UGT2B7 None identified
UGT1A1
UGT1A3 None identified
Transporters for parent statin
OATP1B1, BCRP,
MRP1, 2, 4,
NTCP, P-gp,
OATP1A2, 1B3,
2B1
OATP1B1,
BCRP
OATP1B1, 1B3,
2B1, BCRP OATP1B1, P-gp
OATP1B1, 1B3,
BCRP, MRP2,
NTCP, P-gp
OATP1B1, 1B3, 2B1,
BSEP, BCRP, MRP2,
P-gp; OAT3 in renal
elimination
OATP1B1, BCRP,
BSEP, MRP1, 2, 4, 5,
P-gp, OATP1A2,
1B3, 2B1, NTCP;
OAT3 in renal
elimination
BCRP, P-gp (SVT
acid: OATP1B1)
Metabolites formed
2-OH ATV,
4-OH ATV,
ATV L,
2-OH ATV L,
4-OH ATV L
M-1 acid,
M-23 acid,
CVT L,
M-1 L,
M-23 L
5-OH FVT,
6-OH FVT,
N-deisopropyl
FVT,
FVT L
LVT acid,
6-OH LVT acid PIT L
6-epi PVT,
3α-OH PVT,
PVT L,
3α-OH PVT L
N-desmethyl RVT,
RVT L
SVT acid,
3′,5′-dihydrodiol,
6′-exomethylene
& 3-OH
acid metabolites
Elimination t1/2 (h) 14 2–3 3 2–5 12 1–3 19 2–3
Faecal excretion (%) 98 70 90 83 79 70 90 60
Renal excretion (%) <2 30 5 10 15 20 10–28 13
References [19–25] [19,25–28] [22,25,29] [19,22,25,30,31] [19,22,25,32,33] [22,25,34–38] [19,22,24,25,39–44] [19,22,25,45–48]
ATV = atorvastatin; BCRP = breast cancer resistance protein; BSEP = bile salt export pump; CVT = cerivastatin; CYP = cytochrome P450; FVT = fluvastatin; L = lactone; LVT = lovastatin;
M-1 = demethylation cerivastatin metabolite; M-23 = hydroxylation cerivastatin metabolite; MRP = multidrug resistance-associated protein; NTCP = sodium-taurocholate co-transporting
polypeptide; OATP = organic anion-transporting polypeptide; -OH = hydroxy; P-gp = P-glycoprotein; PIT = pitavastatin; PVT = pravastatin’ RVT = rosuvastatin’ SVT = simvastatin; UGT
= uridine 5′-diphospho-glucuronosyltransferase. † = denotes enzymes with a minor contribution to the known statin metabolism. Drug-metabolising adult CYP3A consists of CYP3A4 and
variable CYP3A5 expression, dependent on CYP3A5 genotype. The underlined transporters are considered particularly important to the disposition of the statin.
J. Clin. Med. 2020, 9, 22 4 of 37
There is notable interindividual variability in response to statin therapy with patients experiencing
variable cholesterol lowering efficacy, recurrent CV events [1,15], and a 45-fold variation in statin
plasma concentrations [49]. Importantly, a small subset of patients experience statin adverse drug
reactions (ADRs), including statin-related myotoxicity (SRM), new-onset diabetes mellitus [50], and
elevated liver transaminases [51,52]. Adverse effects on energy levels and exertional fatigue [53] and
reduced exercise capacity [54] have been reported, but not confirmed [55]. Similarly, there have been
post-marketing case reports of statin-induced memory loss and confusion, although overall, statins are
not currently thought to cause cognitive dysfunction [56,57].
It is important to study SRM because, firstly, it can directly harm patients [58,59]. Secondly,
despite the unequivocal CVD benefit of statins, statin discontinuation and non-adherence rates are high;
~43% of primary prevention and ~24% of secondary prevention patients become statin non-adherent
after a median of ~24 months [60]. Muscle pain increases the likelihood of statin non-adherence and
discontinuation [61] which, importantly, increases the risk of major CV events and mortality [62,63].
2. SRM Definitions
SRM is heterogeneous in presentation (Figure 2) and so case definitions vary between studies.
Therefore, a recent effort has standardised nomenclature and classified SRM into seven distinct
phenotypic categories [64]:
SRM 0 represents asymptomatic elevations in serum creatine kinase (CK) < 4 × the upper limit of
normal (ULN);
SRM 1 and 2 are common myalgias (aches, cramps and/or weakness) with no (SRM 1) or minor
CK elevations (< 4 × ULN, SRM 2);
SRM 3 represents increasingly infrequent myopathy with CK > 4 × but < 10 × ULN;
SRM 4 is severe myopathy with CK > 10 × but < 50 × ULN;
SRM 5 constitutes rare but potentially life-threatening rhabdomyolysis with either CK > 10 ×
ULN, muscle symptoms and renal impairment, or CK > 50 × ULN, and;
SRM 6 consists of very rare anti-HMGCR positive immune-mediated necrotizing myopathy, which
persists despite statin cessation [64].
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Classification and estimated frequencies are based on Alfirevic et al., 2014 [64], except the myalgia
frequency which is from Parker et al., 2013 [65].
Whilst these categories will standardise research, they are perhaps less meaningful as diagnostic
criteria in clinical practice. The National Lipid Association (NLA) defines statin intolerance as the
“inability to tolerate at least two statins: one statin at the lowest starting daily dose and another
statin at any daily dose, due to either objectionable symptoms (real or perceived) or abnormal
laboratory determinations, which are temporally related to statin treatment and reversible upon
statin discontinuation [66].” The European Atherosclerosis Society (EAS) states “the assessment of
statin-associated muscle symptoms includes the nature of muscle symptoms, increased CK levels and
their temporal association with initiation of therapy with statin, and statin therapy suspension and
re-challenge [67].”
3. SRM Clinical Presentation
SRM constitutes the most commonly reported statin adverse event, comprising approximately
two-thirds of all adverse events [68]. The most common muscular symptoms are pain, heaviness,
stiffness and cramps with or without subjective weakness [58,69]. Symptoms involving leg muscles
(thighs, calves) are most frequent, although back, neck, shoulder and generalised muscular symptoms
have also been described [58,69]. Tendonitis-associated pain has been reported [58]. Approximately
40% of patients with SRM note a potential trigger; most commonly, unusual physical exertion or a new
medication [58]. Muscular pains are intermittent in three quarters of SRM patients, and constant in
one quarter [58].
SRM is most common during the first year of treatment [70] with a median time to onset of one
month [51]; over 80% of patients report not experiencing similar symptoms before statin treatment [58].
The muscular symptoms in the majority of SRM cases (~70–80%) are sufficiently intense to disrupt
everyday activities [58,69]; this includes statin persistence and so, can present as MACE. The rarer
severe myopathies and rhabdomyolysis can directly lead to hospitalisation.
4. SRM Frequency
Amongst licensed statins, the frequency of SRM appears highest with SVT, followed by ATV,
and is lowest with FVT [58]. However, the true incidence of SRM is uncertain, occurring in 1.5–5%
of participants in RCTs (relative to placebo groups) [71], compared to ~10–33% in observational
studies [61,72]. This variability is potentially attributable to a range of factors, including different
myotoxicity definitions and follow up procedures, lead-in periods, inclusion of different patient groups,
and treatment blinding [73]. There is consensus that statins increase the risk of severe myopathy
and rhabdomyolysis [50]. Of note, cerivastatin (CVT) was voluntarily withdrawn in 2001 because of
52 cases of fatal rhabdomyolysis [74]. However, the variability in reported SRM rates has sparked
significant disagreement and controversy over the underlying benefit-risk profile of statins, particularly
in patients at the lower end of the CVD risk spectrum [75].
The greater difficulty lies in determining the aetiology of the commoner milder musculoskeletal
symptoms, and in particular, whether they are attributable to a statin and/or concurrent condition(s)
(e.g., viral illnesses). On the one hand, the frequency of muscle-related adverse events did not
differ between patients on ATV 10 mg daily or placebo in the large double-blind ASCOT-LLA RCT
(n = 10,180), but became significantly more common in patients taking ATV 10 mg daily (1.26% per
annum) compared to placebo (1.00% per annum) in the subsequent open label non-blinded extension
phase [76]. This observation was attributed to the nocebo effect. On the other hand, a six-month
double-blind RCT conducted in 420 healthy volunteers administered ATV 80 mg daily or placebo
found increased myalgia amongst the subjects on ATV compared to the placebo group (9.4% vs.
4.6%, respectively, p = 0.05) [65]. Moreover, N-of-1 (single-patient) placebo-controlled trials involving
patients with a history of SRM have reported that ~30–40% experience subsequent muscle-related
events only on statin and not placebo [77,78]. This suggests that the muscle symptoms experienced
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by a third of symptomatic patients are likely statin-induced, whilst the remainder are probably not.
The challenge is how to distinguish patients with true SRM from those with myalgia due to other causes.
5. SRM Pathogenesis
Several SRM risk factors have been identified and mechanisms proposed, but there is not yet
a unified pathophysiological understanding. Nevertheless, two inter-dependent mechanisms are
implicated: 1. increased statin systemic exposure due to clinical and pharmacogenomic factors, which
increase skeletal muscle exposure, and 2. intracellular skeletal myocyte entry and disruption of muscle
function (Figure 3).
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6. Factors Associated with Statin Pharmacokinetics and Myotoxicity
The absorption, distribution, metabolism and elimination (ADME) pharmacokinetic (PK)
characteristics of the different statins are listed in Table 1. Multiple clinical and pharmacogenomic
factors have been associated with statin PK, and a subset also with SRM. These are reviewed below,
with particular focus placed on the pharmacogenomic associations.
6.1. Clinical Factors
The clinical factors associated with statin PK and SRM are listed in Supporting Information Table S1,
and Table 2, respectively. Several, but not all, identified clinical risk factors for SRM are associated
with increased statin exposure (Table 2). Increasing dose increases statin exposure. Increasing age
correlates with modestly greater statin exposure, except for FVT and RVT [29,43]. Women generally
have modestly higher exposure to most statins, except for RVT and ATV. Whilst there is no difference
in mean RVT exposure between genders [79], women have modestly lower circulating ATV levels
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compared to men [21], attributable to higher hydroxylation metabolism. Patients of Asian ancestry have
an approximate 1.5–1.9-fold increase in median RVT exposure compared to Caucasian patients [80],
and so the US Food & Drug Administration (FDA) recommends that Asian patients start with just 5 mg
RVT daily [43]. All statins are predominantly excreted in faeces and so hepatic impairment can result
in several fold increased exposure to several statins (e.g., ATV, FVT) [21,29], although the influence
on RVT is more modest [81]. The association between alcoholism and SRM [82] may be partially
mediated by alcohol-induced hepatic impairment and reduced body mass leading to increased statin
exposure, although alcohol itself also causes myopathy [83]. Renal impairment is only associated with
increased statin exposure for statins that are at least 10% renally excreted, with little impact on ATV or
FVT [21,84]. Thus, the maximum effect of renal impairment is a 3-fold increase in RVT exposure [43].
Importantly, increasing dose, older age, female sex, low body mass index (BMI), liver disease and renal
impairment have all been associated with SRM [64].
Table 2. Clinical risk factors of statin-related myotoxicity.
Category Risk Factor Reference
Demographics
Advanced age (>80 years old) [51,82]
Female gender [51,85]
Low body mass index [73,82]
Ethnicity
Black African [70]
Caribbean
Co-morbidities
Alcohol abuse [82]
Chronic kidney disease [51,82,86,87]
Chronic liver disease [70,88]
Diabetes mellitus [88,89]
Hypertension [90]
Hypothyroidism [88]
Vitamin D deficiency [91–93]
Personal/family factors
Physical exercise [58,94,95]
Personal or family history of muscle pain [58]
Diet
Grapefruit juice (CYP3A inhibition) [96]
Drugs
Higher statin dose [70,73,97]
Corticosteroids [88]
CYP3A inhibitors (particularly for ATV, LVT, SVT)—e.g.,
amiodarone, ciclosporin, clarithromycin, erythromycin,
protease inhibitors (e.g., indinavir, ritonavir)
[98–104]
CYP2C9 inhibitors † (for FVT)—e.g., fluconazole [105]
OATP1B1 inhibition—e.g., gemfibrozil, ciclosporin [99]
Adapted from Alfirevic et al., 2014 [64]. † = in renal transplant patients and limited to the subgroup carrying CYP2C9* 2 or * 3.
6.2. Pharmacogenomic Factors that Affect Statin Pharmacokinetics
A broad overview of the major enzymes and transporters generally involved in statin disposition
is provided in Figure 4. Multiple genes alter statin PK, as summarised in Supporting Information
Table S2; key genes are CYPs, UGTs (uridine 5′-diphospho-glucuronosyltransferases), SLCO1B1 (solute
carrier organic anion transporter family member 1B1) and the eﬄux transporters ABCB1 (adenosine
triphosphate (ATP)-binding cassette subfamily B member 1) and ABCG2, which are reviewed below.
Table 3 lists studies that have investigated SRM pharmacogenomics. Overall, of the statin PK genes
investigated, only SLCO1B1 rs4149056 has been consistently associated with SRM.
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This figure shows the enzymes and transporters that can be involved in the first pass metabolism
of different statins [19,24,38,106–108]. ATV, LVT, and SVT are hydroxylated by CYP3A4/5, and FVT
by CYP2C9. Statin lactonization is mediated by UDP-glucuronosyltransferases. OATP1B1 is central
to the hepatic uptake of statins, although other transporters can be involved. BCRP and/or P-gp
are important in the intestinal and biliary eﬄux of statins, alongside other transporters. The major
enzymes/tra sporters discussed further in this review are underlined.
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Table 3. Pharmacogenomic investigations of statin-related myotoxicity.
Study Design Genes Variants Statin N Endpoint Main Results
Statin Pharmacokinetics
Bai 2019 [109] Co, CG
SLCO1B1
rs4149056
(521T > C,
p.V174A)
RVT 758 Muscle symptoms
+/− ↑CK
-OR 1.74 (95% CI 1.18–2.57), p = 0.0052
-No associations for ABCB1, ABCG2, CYP2C9, SLCO1B3
-GATM—see ‘Muscle-related’ section below
Carr 2019 [110] GWAS, then MA SVT, CVT, ATV(+ others) 7764
CK > 10 × ULN or
rhabdomyolysis
-all statins: OR 2.99 (95% CI 2.34–3.82), p = 2.63 × 10−18
-SVT: OR 5.91 (95% CI 4.10–8.51), p = 1.46 × 10−21
-ATV: no clear associations
Carr 2013 [89] CC, CG SVT, ATV(+ others) 448
Stop statin & CK >
4 × ULN
-all statins: OR 2.08 (95% CI 1.35–3.23), p = 0.005
-SVT: OR 2.13 (95% CI 1.29–3.54), p = 0.014
-COQ2—see ‘Muscle-related’ section below
Floyd 2019 [111] MA, WES SVT, CVT, ATV(+ others) 2552
Muscle symptoms
& CK > 4 × ULN
-No genome-wide significant associations
-rs4149056 in non-fibrate users secondary analysis:
4.01-fold ↑ risk (95% CI 2.61–6.17), p = 5.46 × 10−11
Danik 2013 [112] RCT, CG RVT 4404 Myalgia No association detected
de Keyser 2014 [113] Co, CG SVT, ATV 1939 Statin dosedecrease or switch
-SVT: HR 1.74 (95% CI 1.05–2.88), p = 0.033
-ATV > 20 mg: HR 3.26 (95% CI 1.47–7.35), p = 0.004
-No associations for SVT or ATV in replication set
Link 2008 [86] CC, GWAS SVT 175
CK > 3 × ULN & 5
x baseline, plus ↑
ALT
-SVT 80 mg: OR 4.5 (95% CI 2.6–7.7)
-STV 40mg: OR 2.6 (95% CI 1.3–5.0), p = 0.004
Puccetti 2010 [114] CC, CG ATV, RVT 76
Muscular
intolerance
(muscle symptoms
or ↑ CK or ↑LFTs)
-ATV: OR 2.7 (95% CI 1.3–4.9), p < 0.001
-RVT: no association
-COQ2—see ‘Muscle-related’ section below
Marciante 2011 [115] CC, CGs &GWAS CVT 917
Muscle symptoms
& CK > 10 × ULN
-OR 1.89 (95% CI 1.40–2.56), p = 3.62 × 10−5
-No associations for CYP2C8, UGT1A1/1A3
-RYR2—see ‘Muscle-related’ section below
Voora 2009 [85] RCT, CG ATV, SVT, PVT 452
Stop statin,
myalgia, or CK > 3
× ULN
-OR 1.7 (95% CI 1.04–2.8), p = 0.03.
-Risk highest in patients on SVT.
-No apparent association for PVT
-No associations for CYP2C8, 2C9, 2D6, 3A4
Xiang 2018 [116] MA, CG SVT, CVT, RVT,ATV, PVT 11,008
Multiple-
myalgia to
rhabdomyolysis
-SVT: OR 2.35 (95% CI 1.08–5.12), p = 0.032
-CVT: OR 1.95 (95% 1.47–2.57), p < 0.001
-RVT: OR 1.69 (95% CI 1.07–2.67), p = 0.024
-ATV or PVT: no associations
Elam 2017 [69] CC, CG
SLCO1B1 rs4149056
SVT, ATV, RVT 19
Statin myalgia
confirmed by
re-challenge
-↑myalgia with rs4149056 variant allele (p = 0.039)
-↑myalgia with rs12422149 variant allele (p = 0.001)
-RYR2—see ‘Muscle-related’ section belowSLCO2B1 rs12422149
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Table 3. Cont.
Study Design Genes Variants Statin N Endpoint Main Results
Statin Pharmacokinetics
Ferrari 2014 [117] CC, CG SLCO1B1
rs4149056,
rs2306283 ATV, RVT, SVT 66
CK > 3 × ULN,
irrespective of
symptoms
- rs4149056: OR 8.5 (95% CI 1.7–42.3), p = 0.001
- rs2306283: OR 0.3 (95%CI 0.06–0.91), p = 0.022
-ABCB1: OR 4.5 (95% CI 1.4–14.7), p = 0.001
-No association for ABCG2
ABCB1 1236C > T,3435C > T
Fiegenbaum 2005 [118] Co, CG ABCB1
1236C > T,
2677G > A/T,
3435C > T
SVT 116 Myalgia -↑ endpoint risk with ABCB1 variants (p < 0.05)-No associations with CYP3A4, 3A5
Hoenig 2011 [119] Co, CG ABCB1 3435C > T ATV 117 Myalgia ↑ risk carrying T compared to C allele (p = 0.043)
Mirosevic Skvrce 2015 [120] CC, CG
SLCO1B1 rs4149056
ATV 130
Adverse reactions
(61.7%
myotoxicity);
myalgia to
rhabdomyolysis
-rs4149056: OR 2.3 (95% CI 1.03–4.98), p = 0.043
-rs2231142: OR 2.75 (95% CI 1.10–6.87), p = 0.03
-No association for CYP3A4*22ABCG2 rs2231142
Mirosevic Skvrce 2013 [105] CC, CG ABCG2 rs2231142 FVT 104
Adverse reactions
in renal transplant
patients
(90.4%
myotoxicity)
-rs2231142: OR 4.89 (95% CI 1.42–16.89)
-*2 or *3 carriers: OR 2.44 (95% CI 1.05–5.71), p = 0.037
-↑ risk of endpoint in CYP2C9*2 or *3 carriers on a
CYP2C9 drug inhibitor: OR 6.59, p = 0.027
CYP2C9 *2, *3
Becker 2010 [121] Co, CG CYP3A4 *1B SVT, ATV 1239 Statin dosedecrease or switch
-SVT/ATV: HR 0.46 (95% CI 0.24–0.90), p = 0.023
-SVT only: HR 0.47 (95% CI 0.23–0.96), p = 0.039
-No association for ABCB1
Frudakis 2007 [122] CC, CG CYP2D6 *4 ATV, SVT 263 Stop statin due tomuscle events
-ATV: OR 2.5 (95% CI 1.5–4.4), p = 0.001
-SVT: OR 1.7 (95% CI 0.9–3.2), p = 0.067
Mulder 2001 [123] Co, CG CYP2D6 *3, *4, *5,*2xN SVT 88 Stop statin
↑ risk with CYP2D6 variants (RR = 4.7);
a gene-dose trend
Wilke 2005 [124] CC, CG CYP3A4/5 3A4*1B,3A5*3 ATV 137 Myalgia No main associations detected
Zuccaro 2007 [125] CC, CG CYPs Several ATV, SVT, PVT(+ others) 100
Muscle symptoms
+/− ↑CK No associations for CYP2C9, 2D6, 3A5
Muscle-related
Bai 2019 [109] Co, CG GATM rs9806699 RVT 758 Muscle symptoms
+/− ↑CK OR 0.62 (95% CI 0.41–0.94), p = 0.024
Mangravite 2013 [126] deQTL CG CCs GATM rs9806699rs1719247 SVT 4413
Muscle symptoms
& CK > 3 × ULN
-rs1719247 in LD with top deQTL, rs9806699: r2 = 0.76
-MA: OR 0.60 (95% CI 0.45–0.81), p = 6.0 × 10-4
Carr 2013 [89] CC, CG COQ2 rs4693075 SVT, ATV(+ others) 448
Stop statin & CK >
4 × ULN COQ2 rs4693075: no associations
Oh 2007 [127] CC, CG COQ2 rs6535454rs4693075
ATV, RVT
(+ others) 291
Muscle symptoms
+ stop statin or CK
> 3 × ULN
-rs6535454: OR 2.42 (95% CI 0.99–5.89), p = 0.047
-rs4693075: OR 2.33 (95% CI 1.13–4.81), p = 0.019
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Study Design Genes Variants Statin N Endpoint Main Results
Muscle-related
Puccetti 2010 [114] CC, CG COQ2 rs4693075 ATV, RVT 76
Muscular intolerance
(muscle symptoms or
↑ CK or ↑LFTs)
-RVT: OR 2.6 (95% CI 1.7–4.4), p < 0.001
- ↑ risk of muscular symptoms and ↑ CK with ATV: OR
3.1 (95% CI 1.9–6.4), p < 0.001
Ruano 2011 [128] CC, CG
COQ2 rs4693570
ATV, SVT, RVT
(+ others) 793
Myalgia
-COQ2 rs4693570 (p = 0.000041) or ATP2B1 rs17381194
(p = 0.00079) associated with ↓ risk.
-DMPK rs672348 (p = 0.0016) associated with ↑ risk.
ATP2B1 rs17381194
DMPK rs672348
Vladutiu 2006 [129] CC, CG
CPT2 Several
ATV, CVT, LVT,
SVT
358
Muscle symptoms; CK
↑ reported
Overall, a fourfold ↑ in the number of mutant alleles
(AMPD1 > CPT2/PYGM) in cases vs. statin-tolerant
controls.
PYGM R49X, G204S
AMPD1 Q12X, P48L,K287I
Tsivgoulis 2006 [130] CRs, CG DMPK CTG repeats PVT, ATV, SVT 4
Muscle symptoms or
fatigue & CK ↑
-1 case of each of type 1 myotonic dystrophy (DMPK),
glycogen storage disease V (muscle histochemical
diagnosis), mitochondrial myopathy (muscle biopsy &
biochemical diagnosis), and Kennedy disease (NR3C4)
diagnosed after starting statin and becoming
symptomatic
NR3C4 CAG repeats
Echaniz-Laguna 2010 [131] Co, CG NR3C4 CAG repeats SVT, PVT, ATV
(+ others) 52
Abnormal EMG &
pathological analysis,
if muscle features last
> 3 months after statin
ceased
-5 patients diagnosed with paraneoplastic polymyositis,
Kennedy disease (NR3C4), glycogen storage disease IX
(PHKA1), motor neuron disease, and necrotic myopathy
of uncertain aetiology
PHKA1 Not specified
Knoblauch 2010 [132] CS, CG CNBP CCTG repeat ATV, SVT(+ others) 3
Muscle symptoms that
last after statin ceased
+/− ↑CK
-All 3 cases diagnosed with type II myotonic dystrophy
after becoming symptomatic after starting statin
treatment
Voermans 2005 [133] CR, CG GAA IVS1-13T > G525del T SVT 1
Muscle symptoms &
CK ↑
-1 case of a compound heterozygote for glycogen
storage disease II diagnosed after becoming
symptomatic on SVT
Zeharia 2008 [134] CC, CG LPIN1 sequenced Unknown 20 Myopathy with ↑CK In 2 of 6 cases, exonic nucleotide substitutions thoughtharmful were found, vs. 0 in 14 statin-tolerant controls.
Vladutiu 2011 [135] CC, CG RYR1 34 mutations Not specified 493
Muscle
symptoms-often last
post statin, +/− ↑CK
RYR1 mutations in 3 of 197 severe & 1 of 163 mild statin
myopathies, vs. 0 of 133 statin-tolerant controls
Isackson 2018 [136] WES
RYR1 Pathogenic
variants
ATV, RVT, SVT
(+ others) 126
Muscle symptoms &
CK > 5 × ULN
12 of 76 (16%) of SRM patients had probably pathogenic
variants in RYR1 or CACNA1S, which was 4-fold higher
than in statin-tolerant controls.
CACNA1S
Elam 2017 [69] CC, CG RYR2 rs2819742 SVT, ATV, RVT 19
Statin myalgia
confirmed by
re-challenge
-↑myalgia with rs2819742 variant allele (p = 0.016)
-No associations with GATM, COQ2, HTR3B, HTR7
Marciante 2011 [115] CC, CGs &GWAS RYR2 rs2819742 CVT 917
Muscle symptoms &
CK > 10 × ULN OR 0.48 (95% CI 0.36-0.63), p = 1.74 × 10−7
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Study Design Genes Variants Statin N Endpoint Main Results
Immune-system related
Limaye 2015 [137] Co, CG HLA-DRB1*11
Typing to
‘two-digit’
resolution
Not specified 207
Anti-HMGCR
antibodies in
patients with
idiopathic
inflammatory
myositis or
immune-mediated
necrotizing
myopathy
-Anti-HMGCR antibodies in 19 of 207 myopathy cases
-HLA-DRB1*11 more frequent in myopathy patients
positive vs. negative for anti-HMGCR antibodies:
OR 56.1 (95% CI 5.0–7739), p = 0.001
-3 anti-HMGCR positive myopathy patients had high
resolution typing and all carried HLA-DRB1*11:01
Mammen 2012 [138] CC, HLA typing
HLA-DRB1*11
Typing
resolution:
-Intermediate;
-High in
DR11
Not specified 733
Anti-HMGCR
antibodies in
patients with
myositis/myopathy
-OR for HLA-DRB1*11:01 in anti-HMGCR myopathy
patients vs. controls: ~24.5 (p = 3.2 × 10−10) and
~56.5 (p = 3.1 × 10−6) in white & black ethnicities,
respectively
-HLA-DQA1 and DQB6 less frequent in white
anti-HMGCR positive patients than controls
(p = 5.5 × 10−4, p = 2.1 × 10−5, respectively)
DQA Intermediate
resolutionDQB
Siddiqui 2017 [139] Co, CG LILRB5 rs12975366 SVT, RVT(+ others) 1034
-1. Non-adherence &
↑CK
-2. Statin intolerant
& switched ≥ 2 other
statins
-1: OR 1.81 (95% CI 1.34–2.45)
-2: OR 1.36 (95% CI 1.07–1.73)
Pain perception
Ruano 2007 [140] CC, CG HTR3B rs2276307 ATV, SVT, PVT 195 Myalgia
-↑risk for rs2276307 (p = 0.007) & rs1935349 (p = 0.026)
-No associations for HTR1D, 2A, 2C, 3A, 5A, 6, SLC6A4HTR7 rs1935349
Other
Isackson 2011 [141] GWAS EYS
rs1337512,
rs9342288,
rs3857532
ATV (+ others) 399
Muscle
symptoms-often last
post therapy, +/−
↑CK
EYS SNPs conferred ↑ risk (p = 0.0003–0.0008), but did
not survive multiple testing correction for GWAS.
CC = case-control study; CG = candidate gene; CI = confidence interval; CK = creatine kinase; Co = cohort study; CR = case report; CS = case series; deQTL = differential expression
quantitative trait loci; GWAS = genome-wide association study; HR = hazard ratio; MA = meta-analysis; OR = odds ratio; RCT = randomized controlled trial; WES = whole-exome
sequencing. Studies are ordered to preferentially group those that investigated the same gene(s) together.
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6.2.1. CYP Phase 1 Hydroxylation
Metabolism is responsible for the clearance of 70% of the top 200 used drugs [142], a subset
of 12 of the 57 putatively functional CYPs within the human CYP superfamily carry out 75% of
drug biotransformations [143], and CYP3A metabolises the largest number of different drugs [142].
ATV, LVT and SVT are themselves extensively metabolised by CYP3A, with greater contributions
from CYP3A4 than CYP3A5 [144]. Although no common missense variants are known for CYP3A4,
the intronic variant, rs35599367 (*22, 522-191C > T), is associated with reduced CYP3A4 hepatic
mRNA and enzymatic activity [145]. CYP3A4*22 increases the formation of non-functional CYP3A4
alternate splice variants with partial intron six retention, specifically in human liver but not small
intestine [146]. CYP3A4*22 is present with a minor allele frequency (MAF) of ~5% in Europeans, but
is low/rare (~1%) in African and Asian populations [147]. CYP3A4*22 is associated with reduced
ATV hydroxylation [148] and ethnicity-restricted increases in SVT/SVT acid concentrations [48].
Although nuclear receptors are highly conserved [149], a single nucleotide polymorphism (SNP)
within peroxisome proliferator-activated receptor-α (PPARA), rs4253728, has also been associated with
reduced human hepatic CYP3A4 protein levels [148] and reduced metabolism of ATV [148] and likely
SVT [150].
CYP3A5*3 is a loss of function allele defined by rs776746 (6986G > A), which introduces a cryptic
mRNA splice site resulting in a non-functional truncated protein [151], and has MAFs of ~18%, 69%
and 94% in African, Asian and European populations, respectively [147], indicating allelic reversal.
CYP3A5*3/*3 has been associated with increased SVT and ATV L exposures [152,153].
Increased exposures to LVT [154,155] and SVT [156] have been tentatively reported in association
with CYP2D6 reduction/loss-of-function alleles (e.g., *5, *10, *14). However, in vitro studies have not
identified LVT/SVT as CYP2D6 substrates [47,157,158], which puts these CYP2D6-LVT/SVT associations
into doubt. Carrying CYP2C9*3 has been associated with increased exposures to FVT and PIT, but not
RVT or SVT (Table S2). CYP2C9*2 was not associated with FVT exposure [159]. CYP2C9*2 and *3 are
both reduction-of-function nonsynonymous variants that reduce xenobiotic metabolism by ~30–40%
and ~80–90%, respectively [160]. The MAF of CYP2C9*3 is 7%, 4% and rare in Caucasian, Asian, and
African populations, respectively.
Variants in CYP3A4/5 and CYP2D6 have been inconsistently associated with SRM or statin
tolerability in some candidate gene studies [121–123] but not others [85,118,125]. Carrying CYP2C9*2
or *3 may increase the risk of FVT adverse events (mainly myotoxicity), particularly when also
receiving a CYP2C9 drug inhibitor [105]. However, all patients in this FVT study were renal transplant
recipients [105], and so the generalisability of these findings remains unknown. None of these genes
have yet been identified in SRM genome-wide association studies (GWAS) [86,115,141]. Thus, whilst
CYP genetic variants are linked to altered statin exposure, their relationship with SRM remains uncertain.
6.2.2. UGT1A3 Phase 2 Glucuronidation
The UGT family is involved in phase II drug metabolism and consists of subfamilies UGT1A,
UGT2A and UGT2B [161]. UGTs catalyse glucuronidation, typically transforming small lipophilic
molecules into more hydrophilic metabolites, which are easier to excrete. Statin lactonization can
occur either non-enzymatically at low intestinal pH [162], conceivably via a coenzyme A-dependent
process [163], or via an unstable acyl glucuronide intermediate that undergoes spontaneous cyclization
to a lactone analyte [164]. Statin lactone species are considered more myotoxic than their acid
counterparts [165]. Depending on the statin, UGT1A3, 1A1 and UGT2B7 can be involved in acyl
glucuronidation [19]. However, UGT1A3 has been consistently shown to have the highest in vitro statin
lactonization rates [19]. UGT1A3*2 is associated with increased UGT1A3 hepatocyte protein expression
and *2/*2 volunteers have higher exposures of both ATV lactone and 2-hydroxy ATV lactone [161,166].
The common low expression UGT1A1 dinucleotide tandem repeat promoter polymorphism, *28,
has been associated with both decreased area under the ATV lactone concentration-time curve (AUC) [167]
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and increased lactonization [161]; this discrepancy is likely attributable to the extensive linkage
disequilibrium within the UGT1A locus—for example, between UGT1A1*28 and UGT1A3*2 [161].
UGT1A1/1A3 variants have been sequenced to investigate CVT myotoxicity, but no association was
identified [115]. To date, they have not been included in SRM candidate gene studies, nor identified in
SRM GWAS.
6.2.3. SLCO1B1 Influx Transporter
SLCO1B1, located on chromosome 12p12.2, encodes organic anion-transporting polypeptide
1B1 (OATP1B1), which is a major hepatocyte-specific sinusoidal influx xenobiotic transporter.
The nonsynonymous SNP, rs4149056 (521T > C, p.V174A), in exon five results in decreased intrinsic
OATP1B1 transport activity [168]. The rs4149056 MAF is approximately 1%, 8% and 16% in African,
Asian and European populations, respectively [147]. Importantly, rs4149056 521CC homozygosity has
been associated with increases in statin AUC of 286% (LVT acid) [169], 221% (SVT acid) [170], 208%
(PIT) [171], 144% (ATV) [172], 91% PVT [173], and 65% (RVT) [172]. However, rs4149056 has not been
associated with FVT [173] or parent LVT [169] and SVT exposures [170].
Importantly, rs4149056 was identified in a seminal GWAS to be strongly associated with myopathy
in 85 cases compared to 90 controls, all of whom were on SVT 80mg daily [86]. The odds ratio (OR)
for myopathy in 521CC versus 521TT patients was 16.9 (95% confidence interval (CI) 4.7, 61.1), and a
gene-dose trend was evident with an OR of 4.5 (95% CI 2.6–7.7) per C allele [86]. In patients on 40 mg
SVT daily, the myopathy relative risk remained but was halved to ~2.6 (95% CI 1.3–5.0) per C allele,
in keeping with a dose-related ADR [86]. This association between SVT myopathy and rs4149056 has
been replicated [89,174] and confirmed in recent large meta-analyses [110,116]. Furthermore, rs4149056
has also been linked to milder adverse outcomes encompassing myalgia, prescription reductions
and/or minor biochemical (e.g., CK) elevations indicative of SVT intolerance [69,85,113,175].
In adsition to SVT, historical cases of CVT-related rhabdomyolysis have been associated with
rs4149056 [115]. Furthermore, a recent whole-exome sequencing endeavour reported that SLCO1B1
rs4149056 is associated with statin myopathy (mainly SVT or CVT cases), which reached multiple
testing significance when limited to patients not on a fibrate; however, no novel rare coding signals were
detected [111]. Intriguingly, SLCO1B1 rs4149056 has been recently associated with RVT myotoxicity
(a composite of myalgias to rhabdomyolysis) in Han Chinese patients [109,176], although it was not
previously associated with myalgias in patients of European descent receiving RVT [112]. A recent
meta-analysis, largely including these studies, further suggested an association between rs4149056 and
RVT myotoxicity [116]. Given the increased RVT exposure reported in Asian compared to Caucasian
patients, which is partially but not completed explained by ABCG2 rs2231142 (see Section 6.2.4) [80],
Asian patients are perhaps more sensitive to further SLCO1B1-mediated increases in RVT exposure.
Overall, it has been suggested that rs4149056 might be relevant for severe myopathy (e.g., CK >
10 × ULN) due to several statins, with an effect size likely greatest for SVT (or LVT) and lowest for FVT,
based upon the degree to which the rs4149056 minor C allele increases exposure to each statin [110].
Nevertheless, rs4149056 has not yet been clearly associated with PVT myotoxicity [85,116], and whilst
an association between rs4149056 and ATV myotoxicity has been suggested [85,113] or reported [114],
several other studies found no evidence [89,110,116,174,176–178]. Reasons for ongoing uncertainty
regarding the role of rs4149056 in ATV myotoxicity include fewer ATV cases in studies (especially
cases on high dose ATV) [89] and ATV appears less intrinsically myotoxic than SVT [165], as well as
the impact of rs4149056 on exposure being smaller for ATV than SVT acid [172]. The latter is plausibly
because ATV utilises OATP1B3, 2B1 and 1A2, as well as OATP1B1, for hepatocyte uptake [25].
In summary, the influence of rs4149056 on myotoxicity risk is clear for SVT, but incompletely
resolved for the other licensed statins. Importantly, the FDA revised the SVT product label to reduce SVT
80 mg use because of the elevated myotoxicity risk [179]. Furthermore, the Clinical Pharmacogenetics
Implementation Consortium (CPIC) guidelines recommend a lower SVT starting dose or an alternative
statin, alongside consideration of routine CK surveillance, in patients already known to carry at least
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one 521C allele [180]. The Dutch Pharmacogenetic Working Group (DPWG) has published guidance for
SLCO1B1 rs4149056 and both SVT and ATV [181]. The DPWG SVT guideline first line recommendation
is an alternate statin in 521C carriers, whilst the ATV guidance only recommends an alternate statin in
521C carriers with additional SRM clinical risk factors [181].
6.2.4. ABCB1 and ABCG2 Eﬄux Transporters
ABCB1 and ABCG2 are both members of the superfamily of ATP-binding cassette (ABC)
transporters and encode the eﬄux transporters P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP), respectively. Both P-gp and BCRP are located in the apical (luminal) membrane of
enterocytes and the canalicular membrane of hepatocytes, as well as other locations including the
blood–brain barrier [182] and placenta [183,184]; they have broad substrate specificity.
ABCB1 has three common SNPs, rs1128503 (1236T-C, synonymous), rs2032582 (missense, 2677T-G)
and rs1045642 (synonymous, 3435T-C); TTT homozygotes have ~55–60% increased exposure to both
ATV and SVT acid [185]. The ABCB1 T alleles have been associated with symptom-independent
elevated CK levels [117] and muscle symptoms [118,119] in some candidate gene studies, but not with
prescribing changes suggestive of statin intolerance [121], nor in SRM GWAS [110,115].
The nonsynonymous ABCG2 SNP, rs2231142 (421C > A, p.Q141K), has MAFs of 1%, 10–29% and
9% in African, Asian, and European populations, respectively [147]. The 421AA genotype has been
associated with a 2.4-fold increased exposure to RVT, ~2-fold increased exposures to ATV, FVT, and
SVT, but no increased exposures to PIT or PVT [108]. Interestingly, carrying rs2231142 421A has been
associated with an increased risk of myotoxicity with ATV [120], and in renal transplant recipients
receiving FVT [105]. Both of these studies were small case control candidate gene studies and have not
been confirmed in GWAS, although SRM GWAS analyses have included relatively few FVT cases to
date [86,110,111,115].
6.3. Drug–Statin Interactions
Drug–statin interactions are common, can lead to several fold increases in statin exposure, and
are established SRM risk factors. Ciclosporin is a potent inhibitor of CYP3A4 [186] and several
transporters including OATP1B1, OATP1B3, OATP1B2, ABCG2, and P-gp [99,187], and universally
increases systemic exposure of all statins (Table S1). Gemfibrozil and its glucuronide metabolite inhibit
CYP2C8 and OATP1B1 and increase statin acid levels (except FVT). Importantly, ciclosporin and
gemfibrozil are strongly associated with SRM [99]. CYP3A inhibitors (e.g., amiodarone, itraconazole,
clarithromycin) consistently increase the systemic exposure of the CYP3A-metabolised statins (ATV,
LVT, SVT) and are significant SRM risk factors [98,99]. Similarly, grapefruit juice, which inhibits CYP3A,
has been linked to SVT rhabdomyolysis [96]. The novel cytomegalovirus viral terminase inhibitor,
letermovir, increased ATV AUC by over 200%, attributable to inhibition of OATP1B1/3 and CYP3A, and
is expected to increase exposure to other statins too [188]. Several antiretroviral drugs increase statin
exposure through inhibition of CYP3A and/or OATP1B1, including protease inhibitors (e.g., lopinavir,
saquinavir, tipranavir) and pharmacokinetic enhancers (e.g., ritonavir, cobicistat) [189]. As stated
above, CYP2C9 inhibitors (e.g., fluconazole) may interact with CYP2C9*2 or *3 carriage to increase
FVT myotoxicity [105]. Beyond PK interactions, other drugs themselves linked with myotoxicity,
including corticosteroids and colchicine, may also augment the risk of SRM [88,190]. In recognition
of the importance of these interactions, specific recommendations for the management of clinically
significant statin–drug interactions have been published [190].
7. Statin Uptake into Skeletal Muscle
Elevated systemic statin exposure plausibly increases intra-myocyte statin concentrations. Statin
myocyte entry is likely facilitated by transporters, with statins being substrates for several sarcolemmal
transporters. These include OATP2B1, multidrug resistance-associated protein (MRP) 1, MRP4, MRP5
and MCT4 (monocarboxylate transporter-4) [24,191]. Interestingly, the minor allele of the SLCO2B1
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nonsynonymous variant, rs12422149 (935G > A, p.R312Q), has been associated with increased SVT acid
plasma clearance in population PK modelling [150], and with statin (mainly SVT) myalgia in a small
candidate gene study (n = 19) [69]; both of these findings are potentially consistent with increased
statin muscle uptake. It is also noteworthy that lipophilic statins (ATV, SVT) preferentially accumulate
in skeletal muscle relative to hydrophilic statins (PVT, RVT) [192], which may help explain the greater
myotoxicity of lipophilic statins [165]. The tissue distribution of transporters may also partially account
for the lack of statin cardiomyotoxicity [191].
8. Statin-Induced Myocyte Dysfunction
Several mechanisms of myotoxicity have been proposed, as outlined below. Studies that
investigated the role of muscle-related gene variants in SRM are detailed in Table 3.
8.1. Exercise
Physical exercise has been reported to trigger and exacerbate SRM [58]. Following the Boston
marathon, runners taking a statin had higher CK rises than runners not on a statin [193]. Interestingly,
increasing age was associated with higher CK elevations after the marathon only in those on a
statin [193]. In professional athletes with hypercholesterolaemia, only 20% could tolerate a statin long
term despite re-challenges with alternate statins and doses [194]. Thus, exercise and statins together
can potentiate muscle adverse events [195]. Nevertheless, a systematic review has reported that the
literature is inconsistent on whether statins objectively reduce exercise capacity and performance [55].
Interestingly, whilst the circulating levels of three muscle-specific microRNAs (miR-1, miR-133a,
miR-206) increased after running a marathon irrespective of statin use, the circulating level of a fourth
muscle microRNA, miR-499-5p, only increased 24 h after the marathon in runners taking a statin [196].
Follow-up studies in cultured C2C12 myotubes confirmed that extracellular miR-499-5p increases only
when carbachol-induced muscle contraction is combined with statin exposure [196]. These observations
suggest a role for epigenetics in statin-potentiated muscle injury, and suggest a biomarker for identifying
patients with exercise-exacerbated SRM. Nevertheless, this biomarker requires replication. Lastly, these
microRNA observations are from marathon runners and not necessarily applicable to more common,
moderate exercise. Intriguingly, it has been suggested by some rodent studies that graduated exercise
training can improve muscle tolerance to statin exposure [197,198]. Therefore, the findings that exercise
to different degrees may either exacerbate or protect against SRM suggests that further work is required
in this area to provide patients with clear advice on what to do in terms of exercise and statin use.
8.2. Pre-Existing Neuromuscular Disorders
Statin therapy can adversely interact with underlying neuromuscular disorders to exacerbate
symptoms in patients with diagnosed disorders, or unmask previously asymptomatic disorders [199].
Clinical conditions exacerbated or unmasked by statin exposure include myasthenia gravis,
dermato/polymyositis, inclusion body myositis, motor neuron disease, and MELAS (mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes) [200–202]. MELAS is a rare mitochondrial
disease generally associated with mutations in MT-TL1 (mitochondrially encoded tRNA leucine 1,
also known as TRNL1) and reported patients adversely affected by statin exposure had the MT-TL1
A3243G mutation [201,202]. In such cases, symptoms (muscle-related or otherwise) often persist after
statin cessation [129,203], which is an indication for further investigations in those patients not already
known to have a neuromuscular disorder.
Patients with untreated hypothyroidism, which causes hypercholesterolaemia and hypothyroid
myopathy, are at an increased risk of SRM. This SRM can resolve following statin discontinuation,
or persist until thyroid hormone replacement [204,205].
Several metabolic myopathies have been associated with SRM, and often, patients were
asymptomatic and unaware of the myopathy before starting statin treatment [130]. It is thought
that these conditions increase susceptibility to SRM through reducing the ability of skeletal muscle
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to compensate to statin-induced myotoxic effects. Metabolic myopathies with an identified genetic
mutation that has subsequently been found in patients presenting with SRM include: adenosine
monophosphate deaminase (AMPD1) deficiency (formerly myoadenylate deaminase deficiency) [129],
carnitine palmitoyltransferase 2 (CPT2) deficiency [129], glycogen storage diseases II (Pompe disease;
GAA deficiency) [133], V (McArdle disease, PYGM deficiency) [129] and IX (muscle phosphorylase
b kinase (PHKA1) deficiency) [131], malignant hyperthermia (RYR1, CACNA1S) [135,136], recurrent
childhood myoglobinuria (LPIN1 mutation) [134], and type I (DMPK) [130] and II (CNBP) [132]
myotonic dystrophy. In addition, immune-mediated rippling muscle disease presenting after statin
exposure has been reported [206], and mitochondrial myopathies presenting as rhabdomyolsis have
been unmasked following statin treatment, although mitochondrial genetic mutations were not
identified in these cases [130,207].
By way of example, the carrier frequency for McArdle disease was 12-fold higher in a cohort of
patients with lipid lowering (predominantly statin)-induced myopathy, compared to general population
controls [129]. One patient that developed muscular complaints only after CVT was homozygous
for PYGM 49XX, a genotype of McArdle disease [129]. McArdle disease is an autosomal recessive
disease due to complete deficiency of myophosphorylase (PYGM) activity. Myophosphorylase is a
cytoplasmic enzyme involved in glycogenolysis; myophosphorylase deficiency limits muscle oxidative
phosphorylation most likely due to impaired substrate delivery to mitochondria [208]. The roles
of other select myopathy genes (CPT2, RYR1, CACNA1S) are covered in more detail in the relevant
sections below. Overall, a background of carrying variants or incomplete penetrance of metabolic
myopathies appears to sensitive individuals to statin myotoxicity.
8.3. Mitochondrial Impairment
An important role for mitochondrial impairment in SRM is indicated by the case
reports [130,202,207] and series [129] that identified underlying mitochondrial dysfunction in patients
with (non-resolving) SRM. For example, CPT2 is located within the mitochondrial inner membrane
and undertakes oxidation of long-chain fatty acids in mitochondria alongside CPT1. The carrier
frequency of CPT2 variants associated with CPT2 deficiency was higher in SRM patients compared
to controls [129]. CPT2 deficiency is an autosomal recessive disorder and a patient with genetically
confirmed CP2 deficiency (113LL) was also identified in this study. This patient did have pre-existing
symptoms, exacerbated by CVT [129]. Importantly, in vitro transcriptomic analysis has demonstrated
that CPT2 is amongst the top 1% of genes whose mRNA levels are perturbed by 75 drugs (including
statins) that can cause rhabdomyolysis [209].
In vitro studies have demonstrated that the statin lactone species are markedly more myotoxic
than statin acids, and SVT lactone and FVT lactone are more myotoxic than ATV lactone and PVT
lactone [165]. Following ATV re-challenge, patients with previous SRM had higher systemic exposures
to ATV lactone and 4-hydroxy ATV lactone (plus increased 2-hydroxy and 4-hydroxy ATV metabolite
levels) compared to healthy controls [210]. Lactones have been shown to strongly inhibit (up to 84%)
mitochondrial complex III and reduce respiratory capacity within in vitro myoblasts [192]. Furthermore,
Q0 of complex III was identified in silico to be an off-target binding site for statin lactones (but not statin
acids) [192]. These observations were verified in muscle biopsies from SRM patients, in which complex
III enzyme activity was reduced by 18% [192]. Interestingly, CVT lactone showed the greatest degree
of complex III inhibition [192], in keeping with its pronounced rhabdomyolysis risk [74]. In contrast,
a recent study in healthy male volunteers found no major differences in mitochondrial respiratory
capacity after two weeks of daily SVT (80 mg) or PVT (40 mg). However, this study did find a trend
for increased sensitivity to the complex I-linked substrate, glutamate, after SVT treatment, which
might be an early indicator of adverse effects on skeletal muscle [211]. Moreover in primary human
skeletal muscle cells (myotubes), SVT has been shown to impair respiration at mitochondrial complex
I, increase mitochondrial oxidative stress through generation of reactive oxygen species (mitochondrial
superoxide and hydrogen peroxide), and result in myotube apoptosis [212]. Other studies have
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reported that statin exposure does not affect the mitochondrial membrane potential [192,213,214], and
so statins are unlikely to act as a mitochondrial uncoupler. Lastly, a recent in vitro study has reported
that CVT-induced muscle mitochondrial dysfunction is associated with decreased intracellular miR-145
and increased pro-apoptotic gene expression (APAF1, CASP10); enforced miR-145 expression reduced
the apoptotic cell population. However, this study was in a rhabdomyosarcoma cell line and requires
replication [215].
Overall, the evidence strongly supports mitochondrial dysfunction in SRM pathogenesis. However,
further clarity and unification on the mechanisms are required.
8.4. HMGCR Pathway Mediated Effects
Statin inhibition of HMGCR perturbs the mevalonate pathway (Figure 1). Whilst this perturbation
has been linked to possible beneficial pleiotropic effects [12], importantly, the decreases in CoQ10,
protein prenylation, and cholesterol itself have all also been implicated in SRM.
8.4.1. Coenzyme Q10 Depletion
CoQ10 is an important cofactor in mitochondrial respiration [216]. Primary CoQ10 deficiency
is a clinically and genetically heterogeneous condition, considered autosomal recessive, and has
been associated with isolated myopathy, encephalopathy, nephrotic syndrome, cerebellar ataxia and
severe infantile multisystemic disease [217]. In patients on statins, reduced circulating CoQ10 is
routinely observed [216] and a modest decrease in muscle CoQ10 has been suggested in some [218]
but not other studies [211,219]. COQ2 encodes para-hydroxybenzoate-polyprenyl transferase, and
defective COQ2 has been associated with primary CoQ10 deficiency, which can improve with early
CoQ10 supplementation [220]. COQ2 variants, and in particular rs4693075 (1022C > G), have been
investigated; some candidate gene studies [114,127], but not others [89], have reported an association
with SRM. Importantly, a recent meta-analysis of RCTs found that CoQ10 supplementation likely does
not reduce SRM, although larger trials are required to confirm this conclusion [221]. One possible
explanation for this null result is that the Q0 site of mitochondrial complex III is involved in the transfer
of electrons from CoQ10 to cytochrome c, and Q0 is also the off-target binding site for statin lactones
(Section 8.3) [192]. Therefore, statins appear to both reduce circulating CoQ10 and compete for its
pharmacodynamic (PD) target; thus CoQ10 supplementation alone may insufficiently counteract both
statin actions.
8.4.2. Reduced Protein Prenylation
Farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are both downstream
metabolites of mevalonate, and facilitate post-translational prenylation of multiple proteins [222]. GGPP,
rather than FPP, is consistently implicated in in vitro statin myotoxicity [213,223–225]. Experimental
evidence has suggested that the statin-mediated decrease in GGPP reduces myotube ATP levels [213],
blocks prenylation of small GTPases including Rab [213,224,226] and RhoA [225], induces atrogin-1
expression [227], and stimulates apoptosis [213,225]. The possible pathways that culminate in apoptosis
include RhoA mis-localisation from the cell membrane to the cytoplasm (examined in fibroblasts) [225],
inhibition of AKT (protein kinase B) phosphorylation and activation [228] likely via both statin-mediated
ATP depletion through mitochondrial dysfunction and loss of Rab1 activity [229], and dose-dependent
caspase-3 activation [225].
8.4.3. Cholesterol Depletion
The depletion of cholesterol itself has been posited as an aetiological factor in SRM pathogenesis.
Slight skeletal muscle damage has been found by electron microscopy in skeletal muscle biopsies
from asymptomatic statin-treated patients, with a characteristic pattern involving T-tubular system
breakdown and sub-sarcolemmal rupture [230]; cholesterol extraction could reproduce these findings
in vitro in skeletal muscle fibres [230]. Nevertheless, although statins inhibit de novo cholesterol
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production in C2C12 myotubes, total intracellular cholesterol pools remain unchanged [219].
Furthermore, the PCSK9 inhibitors, alirocumab and evolocumab, even more potently reduce LDL-C than
statins, but do not currently appear to increase muscle-related adverse events [231,232]. This suggests
that SRM is more statin-specific than cholesterol-specific.
8.5. Atrogin-1 Upregulation
The F-box protein, atrogin-1, is a tissue-specific ubiquitin protein E3 ligase that appears central to
mediating the proteolysis associated with muscle atrophy observed in multiple diseases, including
diabetes and renal failure [233]. Atrogin-1 expression is significantly higher in muscle biopsies
from patients with SRM, and atrogin-1 knock down in zebrafish embryos prevented LVT-induced
myotoxicity [234]. Moreover, it has been shown that SVT-mediated inhibition of AKT phosphorylation
is associated with upregulation of atrogin-1 mRNA [229].
8.6. Calcium Signalling Disruption
RYR1 (chromosome 19) and RYR3 (chromosome 15) mediate the release of stored calcium ions from
skeletal muscle sarcoplasmic reticulum, and thereby, play a role in triggering muscle contraction [235].
Deleterious RYR1 variants are associated with anaesthesia-induced malignant hyperthermia, central
core disease [236] and multi-minicore disease [237]. CACNA1S encodes the alpha-1 subunit of the
L-type calcium channel (the dihydropyridine receptor) which associates with RYR1 in skeletal muscle,
and CACNA1S mutations are associated with malignant hyperthermia and hypokalaemic periodic
paralysis. Importantly, disease-causing mutations or variants in RYR1 and CACNA1S have been found
to be more frequent in statin myopathy patients than controls [135,136]. Furthermore, muscle biopsies
from patients with SRM express significantly higher RYR3 mRNA and have more severe structural
damage, including intracellular T-tubular vacuolisation, than both statin-naïve and statin tolerant
controls [238].
A recent study that examined statin-treated human and rat muscle tissue identified that statin
treatment causes dissociation of the stabilising protein, FKBP12, from RYR1 in skeletal muscle, and
this is associated with increased unwarranted calcium release sparks [197]. In vitro evidence further
suggested that uptake of calcium by mitochondria stimulates reactive oxygen/reactive nitrogen species
generation that, in turn, act on RYR1 to maintain and/or exacerbate this calcium release from the
sarcoplasmic reticulum. Nevertheless, although the calcium sparks were associated with upregulation
of pro-apoptotic signalling markers (caspase-3 and the proportion of TUNEL positive nuclei), statin
treatment had no impact on muscle force production [197], and so other susceptibility factors are
likely required for myotoxicity to manifest. In rats, running wheel exercise normalised FKBP12-RYR1
binding, which suggests a mechanism by which graduated exercise may improve statin tolerance.
Statin treatment also had minimal effect on calcium sparks from statin-treated rat cardiac tissue [197].
Lastly, the intronic variant, rs2819742 (1559G > A), in RYR2 (chromosome one) was suggestively
associated with CVT severe myopathy by GWAS [115]. The minor A allele was associated with reduced
myopathy risk (OR 0.48, 95% CI 0.36, 0.63, p = 1.74 × 10−7) [115]. Similarly, a small candidate gene
study (n = 19) also identified the G allele of RYR2 rs2819742 to be significantly more common in statin
myalgia cases to statin-tolerant controls, in keeping with the GWAS finding [69]. However unlike
RYR1/RYR3, RYR2 is expressed mainly in cardiac muscle tissue and deleterious RYR2 mutations are
associated with ventricular arrhythmias [239]. Therefore, the relevance of RYR2 rs2819742 to SRM
remains unclear.
8.7. Glycine Amidinotransferase (GATM)
A genome-wide expression quantitative expression loci (eQTL) analysis in lymphoblastoid cell
lines derived from 480 clinical trial subjects identified rs9806699 as a cis-eQTL for GATM, which
interacted with in vitro SVT exposure such that it was a significantly stronger eQTL under SVT-exposed
versus control conditions [126]. GATM is involved in creatine synthesis, and phosphorylation of
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creatine by CK is a major mechanism for muscle energy storage. The GATM locus was associated with
a reduced incidence of statin myopathy in two separate populations (combined SVT, ATV, PVT) with a
meta-analysis OR for rs1719247 of 0.60 (95% CI 0.45–0.81, p = 6.0 × 10−4) [126]. Several subsequent
SRM studies of SRM have not replicated this finding [110,111,240–242], although a recent candidate
gene study of RVT myotoxicity in Han Chinese patients found a similar marginal protective effect of
the GATM rs9806699 minor allele (p = 0.024) [109]. The lack of replication raises questions about the
role of GATM in SRM; functional studies of GATM in human primary muscle cells may help resolve
the discordant results.
8.8. Immunologically-Mediated Statin Myopathy
8.8.1. LILRB5
A GWAS of serum CK levels found strong signals with the muscle CK (CKM) gene and a missense
variant, rs12975366 (D247G), within leukocyte immunoglobulin-like receptor subfamily B member
5 (LILRB5) [243]; these results were replicated in statin users and non-users [243]. Subsequently,
D247 homozygosity has been associated with an increased risk of statin intolerance (a definition not
reliant on CK), and replicated in two of three separate cohorts of patients with either myalgia on RVT,
or statin myopathy (meta-analysis OR 1.34, 95% CI 1.16-1.54, p = 7 × 10−5) [139]. CK levels were
included as a covariate, where appropriate. Subgroup analysis in the included RCT interestingly
showed that, whilst D247 homozygosity was associated with myalgia with both placebo and RVT,
those carrying 247G only had an increased myalgia risk if on RVT. Thus, whilst D247 homozygosity
might confer an overall greater risk of myalgia, statin-induced myalgia appears associated with 247G.
A randomized cross-over experimental medicine study to further investigate this drug-gene interaction
is being undertaken [244]. Although the exact aetiology is unknown, the immune system is involved
in the repair of skeletal muscles and the influx of Foxp3 + T regulatory cells are crucial to muscle
regeneration [245]; interestingly, LILRB5 D247 may associate with FOXP3 expression [139].
8.8.2. HLA-DRB1*11:01
Interestingly, several research groups previously noted that symptoms and CK elevation in a
few patients with SRM persist and/or progress after statin discontinuation, and furthermore, these
patients benefit from immunosuppressive therapy [246–248]. These features are consistent with an
autoimmune phenomenon. In 2011, it was reported that these patients, as well as a minority without
prior statin exposure (less than 10% in myopathy patients ≥ 50 years old), are positive for anti-HMGCR
autoantibodies [249]. Muscle biopsies often show necrotizing myopathy with minimal lymphocytic
infiltration [137,250], and so anti-HMGCR positive myopathy is recognised as a distinct subtype of
immune-mediated necrotizing myopathy [251]. Pharmacogenomic studies have provided further
evidence of an autoimmune aetiology. Importantly, HLA-DRB1*11:01 has been significantly associated
with anti-HMGCR positive myopathy [137,138], and the ORs for the presence of HLA-DRB1*11:01 in
anti-HMGCR myopathy white or black patients, compared to controls, have been estimated to be ~25
and ~57, respectively [138]. HLA-DRB1*11:01 has also been associated with the development of anti-Ro
antibodies in neonatal lupus. Although the underlying aetiology of immune-mediated necrotizing
myopathy remains incompletely resolved, a potential role for anti-HMGCR in its pathogenesis is
suggested: muscle HMGCR expression is upregulated in anti-HMGCR positive myopathy patients [249],
circulating anti-HMGCR levels correlate with CK concentration and disease activity [252], and
anti-HMGCR can impair muscle regeneration and induce muscle atrophy [253].
8.9. Pain Perception
A family history of muscular symptoms with or without statin exposure increases the risk of
SRM [58,69]. A candidate gene study in 195 statin-treated patients, of whom 51 experienced at least
probable myalgia, found that rs2276307 and rs1935349 in the 5-hydroxytryptamine (5-HT, serotonin)
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receptor genes (HTR), HTR3B and HTR7, respectively, were significantly associated with myalgia
score [140]. This suggests that variants that may produce individual differences in pain perception
might play a role in statin-taking patients’ reports of muscle pain [140]. No 5-HT-related candidate SNP
was associated with serum CK level [140], suggesting that the associations are with pain perception
rather than the extent of muscle breakdown. Nevertheless, these associations have not been replicated
in SRM GWAS analyses [86,110,115], although these GWAS analyses used CK elevation (muscle
breakdown) within their case definition [86,110,115]. Moreover, these associations were not identified
in a small (n = 19) candidate gene study of statin myalgia [69]. Overall, an assessment in a larger cohort
with statin myalgia cases will help finalise the relevance of these findings.
8.10. Muscle Transcriptomics
The multifaceted and complex pathogenesis of SRM has been underlined by a recent study that
compared muscle transcriptomic profiles in 26 cases of strictly phenotyped statin myalgia undergoing
statin re-challenge (75% re-developed muscle symptoms) to 10 statin-tolerant controls, with most
taking SVT [69]. A robust separation in skeletal muscle differentially expressed genes was found that
highlighted the roles of mitochondrial stress, cell senescence and apoptosis, localised activation of
a pro-inflammatory immune response, and altered cell and calcium signalling mediated by protein
prenylation and Ras-GTPase activation, in statin myalgia [69]. For example, the insulin/IGF/PI3K/AKT
signalling network was the top perturbed canonical pathway. Within this network, calmodulin
(CALM) was upregulated [69]. CALM is a calcium sensing protein that interacts with RYR1, and the
calcium-calmodulin complex inhibits RYR1 [254]. Alternatively, inositol 1, 4, 5-triphosphate receptor 2
(ITPR2) can medicate calcium release from the sarcoplasmic reticulum [255], and was downregulated
within this network [69]. These differential patterns of regulation likely influence calcium signalling
and are conceivably an adaptive response to the increased RYR1-mediated calcium release sparks
identified following statin-dependent FKBP12 dissociation from RYR1 (described in Section 8.6) [197].
The two most strongly upregulated genes were antisense RNA to the HECT domain E3 ubiquitin
protein ligase 2 (HECTD2-AS1) and uncoupling protein 3 (UCP3). HECTD2 is pro-inflammatory,
whilst UCP3 is a mitochondrial anion carrier protein posited to protect against oxidative stress [69].
Although atrogin-1 ubiquitin E3 ligase was not differentially expressed in this study, several genes of
the ubiquitin ligase pathway (including HECTD2) did feature prominently in this study [69].
8.11. Vitamin D
The vitamin D family are a group of fat-soluble secosteroids that are instrumental in the regulation
of calcium and phosphate levels, and bone mineralisation; the most important forms in humans are
cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). The major natural source of vitamin
D is via the conversion of 7-dehydrocholesterol (endogenously synthesised from cholesterol) to
cholecalciferol by UV-B light, although ergocalciferol and cholecalciferol can also be obtained from
plant and animal-derived dietary sources, respectively [256]. Vitamin D is inactive and so undergoes
sequential hydroxylation, first to 25-hydroxycholecalciferol/25-hydroxyergocalciferol, which are the
major circulating forms but also inactive, and then to 1, 25-dihydroxycholecalciferol (calcitriol)/1,
25-dihydroxyergocalciferol (collectively 1, 25(OH)2D) that constitute the biologically active vitamin D
species [256]. 1,25(OH)2D acts through the vitamin D receptor, which is located in multiple tissues
including bone, kidney, intestine, parathyroid glands and skeletal muscle, to mediate genomic and
faster non-genomic actions [256,257].
There is controversy regarding the impact of statins on vitamin D level [258]. Nevertheless, 1,
25(OH)2D induces CYP3A4 [259,260] and consistent with this finding, the oral availability and systemic
exposure of the CYP3A4 substrate, midazolam, trends higher in winter than summer [261]. Similarly,
vitamin D supplementation reduces ATV exposure [262]. However, paradoxically, low vitamin D levels
may blunt lipid-lowering response to ATV, perhaps because vitamin D derivatives can also inhibit
HMGCR [256]. Vitamin D deficiency causes osteomalacia/rickets, as well as muscle weakness and
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myopathy. Importantly, a meta-analysis has confirmed that plasma vitamin D levels are significantly
lower in statin-treated patients with myalgia, compared to those without [93]. Furthermore, several
(non-randomized) clinical studies have reported that vitamin D supplementation effectively reduces
incident SRM in patients previously statin intolerant undergoing re-challenge, particularly when
previously low vitamin D levels are documented to become normalised [91,263–265]. Based on these
findings, a double-blind adequately powered RCT is now required.
9. Management of SRM
As statins are widely prescribed, mild SRM is commonly encountered in clinical practice,
although statin rhabdomyolysis remains rare. For a patient presenting with SRM, an initial CK
level should be taken. During the consultation, the EAS recommend an evaluation of clinical risk
factors for SRM (Table 2), other causes of muscular complaints (e.g., polymyalgia rheumatica), and
to review the indication for statin therapy, particularly in those at low CVD risk [67]. The benefits
and risks of continuing, temporarily suspending, and discontinuing statin treatment need to be
weighed up. Additional patient counselling involves discussion about the nocebo effect and
complimentary therapeutic lifestyle changes (e.g., smoking cessation, blood pressure control, adopting
the Mediterranean diet) [67,266]. There is no gold-standard diagnostic method nor a validated
questionnaire for SRM, although a myalgia clinical index score has been proposed by the NLA [267].
Nevertheless, the majority of patients that discontinue statin treatment after a statin-related event can
subsequently tolerate some form of statin therapy if re-challenged [268]. In patients with SRM and an
ongoing statin indication, temporary statin withdrawal is often appropriate, followed by one or more
statin re-challenges (post washout), which can aid causality assessment. Re-challenges can use the
same statin (at same dose), an alternate statin at usual dose, lower doses (with potential up-titration),
and/or intermittent (non-daily) dosing using a high intensity statin with a long half-life (e.g., ATV,
RVT) [67]. The aim should be to treat with the maximum tolerated dose required for the indication [7].
Patients should also be informed that any statin at any dose lowers CVD risk [7]. Nevertheless, whilst
less intense approaches such as intermittent dosing are tolerated in at least 70% of patients, they lead
to a variable and likely lower proportion of patients reaching LDL-C goals [269], which should also be
discussed. In those that do not reach LDL-C goals, non-statin lipid lowering therapy can be considered
in combination with the maximally tolerated statin dose or as monotherapy; available options include
ezetimibe, a fibrate, or PCSK9 inhibitor. If considering fibrate therapy, fenofibrate is preferred, and
gemfibrozil should be avoided because of its interaction with statins to increase rhabdomyolysis
risk [67]. Alirocumab and evolocumab have demonstrated cardiovascular benefit in clinical outcomes
trials [231,270]. Moreover, in statin-intolerant patients, these PCSK9 inhibitors are tolerated by > 80%,
reduce LDL-C by 45–56%, and have fewer muscular adverse events than ATV re-challenge [232,271].
Nevertheless, the costs of PCSK9 inhibitors remain high. As a consequence, this often limits their use
to select patients with severe dyslipidaemia [272], and is prohibitive for broader adoption in CVD
prevention [273].
Recently, bempedoic acid has shown promise in patients unable to tolerate more than low-dose
statin therapy. Bempedoic acid is a novel oral agent under development that inhibits ATP citrate lyase,
and a phase 3 RCT showed it reduced LDL-C by 28.5% more than placebo, without a greater rate of
muscle-related events. Of note, ATP citrate lyase is upstream of HMGCR, but bempedoic acid is a
prodrug that requires very-long chain acyl-CoA synthetase-1 (ASCV1L) for bioactivation. ASCV1L
is expressed predominantly in the liver and so it is plausible that the limited active bempedoic acid
in muscle will reduce any potential for myotoxicity. It is also noteworthy that a large multicentre
implementation initiative is pre-emptively genotyping patients starting one of 39 drugs for over
45 pharmacogenomic variants, and prospectively determining the incidence of ADRs compared to
standard care [274]. For patients starting SVT (or ATV) with at least one SLCO1B1 rs4149056 minor
allele, the DPWG recommendations are provided to them and their healthcare team [274].
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10. Conclusions
Despite the development of PCSK9 inhibitors, and ongoing development of novel promising
therapeutics including bempedoic acid [275] and inclisiran [276], the undoubted efficacy, affordability,
availability, and widespread experience with statins ensure they will likely remain the cornerstone of
lipid lowering therapy for the foreseeable future. Thus, understanding and mitigating SRM remains
clinically relevant. The majority of SRM is mild and ceases quickly after statin cessation. In patients in
whom symptoms persist, a non-statin related diagnosis is most likely, although an unmasked metabolic
myopathy, or immune-mediated anti-HMGCR positive myopathy, should also be considered. SRM can
cause direct patient harm, and the links between muscular symptoms, suboptimal statin utilisation,
and increased MACE are clear [61–63]. Several factors that increase systemic statin exposure are
associated with SRM, including higher statin dose, advanced age, drug-drug interactions and, for SVT,
SLCO1B1 rs4149056. Increased systemic statin (lactone) exposure, in turn, predisposes to downstream
deleterious effects on skeletal muscle. The most important appear to be mitochondrial dysfunction,
calcium signalling disruption and reduced prenylation, whose sequelae include atrogin-1 mediated
atrophy, apoptosis, and likely reduced immune-mediated muscle regeneration.
At present, our potential to predict SRM is limited. The parsimonious ‘QStatin’ model for
statin moderate-severe myopathy [70] has been developed, which includes new statin use, ethnicity,
co-morbidities (liver disease, hypothyroidism, diabetes mellitus) corticosteroids, age and BMI,
although its area under the receiver operator curve of ~0.7 is modest [88]. The implementation
of SLCO1B1 rs4149056 testing [274] may help improve predictive power. Whilst the association
between HLA-DRB1*11:01 and anti-HMGCR positive myopathy is notably strong, HLA-DRB1*11:01
will likely be insufficient to predict this condition alone given its rarity, but HLA-DRB1*11:01 may have
utility in excluding the diagnosis.
Overall, further research is critically needed to identify, validate and integrate novel risk factors for
the different SRM phenotypes to improve predictive capability and harmonise understanding of SRM
pathogenesis. We propose that the integration of strict clinical phenotyping to identify statin-induced
myalgia through the N-of-1 trial paradigm [277], with systems pharmacology omics-based approaches,
should be beneficial. Replication of the miR-499-5p and miR-145 signals is needed. The interactions
between exercise and vitamin D status with statin use warrant further study. Increased research is
also needed into the gut microbiome, as it has recently been shown to be significantly perturbed by
statins [278,279] and might module statin response [280]. Much has been done; much work remains.
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